Nadim Ahmed Net Worth

The estimated Net Worth of Nadim Ahmed is at least $5.49 Million dollars as of 26 December 2023. Mr. Ahmed owns over 4,272 units of Bristol-Myers Squibb Co stock worth over $5,420,215 and over the last 6 years he sold BMY stock worth over $69,597. In addition, he makes $0 as Executive Vice President and President - Hematology at Bristol-Myers Squibb Co.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ahmed BMY stock SEC Form 4 insiders trading

Nadim has made over 16 trades of the Bristol-Myers Squibb Co stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 4,272 units of BMY stock worth $39,473 on 26 December 2023.

The largest trade he's ever made was exercising 17,204 units of Bristol-Myers Squibb Co stock on 1 March 2020 worth over $835,942. On average, Nadim trades about 2,079 units every 52 days since 2018. As of 26 December 2023 he still owns at least 111,550 units of Bristol-Myers Squibb Co stock.

You can see the complete history of Mr. Ahmed stock trades at the bottom of the page.

Nadim Ahmed biography

Nadim Ahmed serves as Executive Vice President and President - Hematology of the Company. 2014 to 2016 – Corporate Vice President, U.S. Commercial, Celgene 2016 to 2017 – Senior Vice President Worldwide Markets, Celgene 2017 to 2019 – Executive Vice President/President Hematology/Oncology, Celgene 2019 to present – Executive Vice President and President, Hematology

How old is Nadim Ahmed?

Nadim Ahmed is 52, he's been the Executive Vice President and President - Hematology of Bristol-Myers Squibb Co since 2019. There are 28 older and 7 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.

What's Nadim Ahmed's mailing address?

Nadim's mailing address filed with the SEC is C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.

Insiders trading at Bristol-Myers Squibb Co

Over the last 16 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius, and Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.

What does Bristol-Myers Squibb Co do?

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Complete history of Mr. Ahmed stock trades at Bristol-Myers Squibb Co and Cullinan Oncology

Bristol-Myers Squibb Co executives and stock owners

Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include:

• Giovanni Caforio,
  Chairman of the Board, Chief Executive Officer
• Sandra Leung,
  Executive Vice President, General Counsel
• Dr. Giovanni Caforio M.D.,
  Chairman & CEO
• Christopher Boerner,
  Executive Vice President and Chief Commercial Officer
• David Elkins,
  Executive Vice President and Chief Financial Officer Member of the Leadership Team
• Rupert Vessey,
  Executive Vice President, Research and Early Development Member of the Leadership Team
• Louis Schmukler,
  Executive Vice President, President - Global Product Development and Supply
• David V. Elkins,
  Exec. VP & CFO
• Rupert Vessey BCH, BM, DPHIL, M.A.,
  Exec. VP and Pres of Research & Early Devel.
• Sandra Leung Esq.,
  Exec. VP & Gen. Counsel
• Dr. Christopher S. Boerner,
  Exec. VP & Chief Commercialization Officer
• Vicki Sato,
  Lead Independent Director
• Matthew Emmens,
  Independent Director
• Peter Arduini,
  Independent Director
• Dinesh Paliwal,
  Independent Director
• Theodore Samuels,
  Independent Director
• Karen Vousden,
  Independent Director
• Robert Bertolini,
  Independent Director
• Gerald Storch,
  Independent Director
• Phyllis Yale,
  Independent Director
• Julia Haller,
  Independent Director
• Michael Bonney,
  Independent Director
• Derica Rice,
  Independent Director
• Paula Price,
  Independent Director
• Tim Power,
  Vice President of Investor Relations
• Joseph Eid,
  Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team
• Karen Santiago,
  Senior Vice President, Corporate Controller
• Adam Dubow,
  Senior Vice President, Chief Compliance Officer and Ethics Officer
• Paul von Autenried,
  Chief Information Officer, Senior Vice President
• Elizabeth Mily,
  Executive Vice President - Strategy & Business Development
• Kathryn Metcalfe,
  Executive Vice President - Corporate Affairs Member of the Leadership Team
• Samit Hirawat,
  Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team
• Nadim Ahmed,
  Executive Vice President and President - Hematology
• John Elicker,
  Executive Vice President of Investor Relations
• Ann Judge,
  Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
• Ann M. Powell Judge,
  Exec. VP & Chief HR Officer
• Adam Dubow,
  Sr. VP, Chief Compliance & Ethics Officer
• Timothy Power,
  VP & Head of Investor Relations
• Paul von Autenried,
  Exec. VP & Chief Information Officer
• Greg Meyers,
  Exec. VP and Chief Digital & Technology Officer
• Jose Baselga,
  Director
• Alan J Lacy,
  Director
• Joseph C Caldarella,
  VP & Financial Controller
• Anne Nielsen,
  Chief Compliance & Ethics Off
• Laurie H M.D. Glimcher,
  Director
• Michael Grobstein,
  Director
• Togo D Jr West,
  Director
• Emmanuel Blin,
  SVP, Head of Commercialization
• Francis M Cuss,
  SVP Dscvry & Exp Clinl Resrch
• Murdo Gordon,
  SVP, Head of Worldwide Markets
• Thomas J. Jr. Lynch,
  Director
• Karin Shanahan,
  EVP, Glob. Prod. Dev. & Supply
• Lynelle Hoch,
  President, Cell Therapy Org.
• Phil M Holzer,
  SVP and Controller
• Ahn Amanda Poole,
  EVP, Chief Human Resources
• Samuel J Moed,
  SVP, Strat Plan & Analysis
• Michelle Weese,
  EVP, Corporate Affairs
• Paul Biondi,
  SVP, Head of Strategy & BD
• Charles A Bancroft,
  EVP, Head of Integration
• Ann Powell,
  EVP, Chief Human Resources
• Frances K Heller,
  SVP, Business Development
• Brian Daniels,
  SVP Global Development
• Elliot Sigal,
  EVP, CSO & President R&D
• Beatrice J Cazala,
  SVP Comm Ops & Pres GC Euro EM
• Robert T Zito,
  SVP & Chief Comm Officer
• Jeremy M Levin,
  SVP Strat Transactions
• R Sanders Williams,
  Director
• Anthony C Hooper,
  President US Pharmaceuticals
• Louis J Freeh,
  Director
• Anthony A Mcbride,
  SVP Human Resources
• De Notaristefani Carlo,
  President, Tech Ops
• Leif Johansson,
  Director
• John E Celentano,
  SVP Strat & Productivity Trans
• Jean Marc Huet,
  SVP & CFO
• James M Cornelius,
  Chairman & CEO
• Lewis B Campbell,
  Director
• Medina Manuel Hidalgo,
  Director
• Benjamin Hickey,
  President, RayzeBio Org.
• Gregory Scott Meyers,
  EVP, Chief Digital & Tech Off.
• Sharon Greenlees,
  SVP & Controller
• Deepak Bhatt,
  Director
• Michael R. Mc Mullen,
  Director
• Adam Lenkowsky,
  EVP, Chief Commercial Officer
• Robert M Plenge,
  EVP, Chief Research Officer
• Cari Gallman,
  EVP, Corporate Affairs